Nanoparticles in breast cancer therapy
DOI:
https://doi.org/10.61173/qrwmbb91Keywords:
Nanotechnology, Nanoparticles, Breast Cancer therapyAbstract
Nanoparticles have been popular as therapeutic agents for breast cancer due to their distinct properties and wide range of applications. Nanoparticles, which are extremely small and have a high surface area-to-volume ratio, have several benefits, including improved drug solubility, precise delivery to specific targets, and longer circulation in the body. Their targeted drug delivery systems minimize exposure to neighboring healthy cells, reducing potential side effects. Encapsulation of drugs within nanoparticles improves efficacy and stability while protecting them from premature metabolism and degradation. Additionally, nanoparticles facilitate combination therapy by carrying multiple therapeutic agents simultaneously, targeting different aspects of cancer progression. Lipid-based, polymer-based, inorganic, and hybrid nanoparticles are prominent types of nanoparticles utilized in clinical breast cancer treatment. Nanoparticle-based cancer therapy utilizes nanoparticles to deliver therapeutic agents directly to the tumor site, maximizing the therapeutic effect. This article provides a thorough examination of various nanoparticle varieties and their therapeutic applications in the treatment of breast cancer.
References
P-glycoprotein in vitro, as compared to free DOX solu- treatments. International Immunopharmacology, 2020. 84: p. tions. This highlights the crucial role of incorporating 106535. drug, polymer, and lipid components into nanoparticle [4]Zhong, L., et al., Small molecules in targeted cancer form to promote cytotoxicity, drug uptake, and retention therapy: advances, challenges, and future perspectives. Signal [26]. Transduction and Targeted Therapy, 2021. 6(1): p. 201. [5]Kumar, P., et al., A review of nanomaterials from synthetic and 6. Summary natural molecules for prospective breast cancer nanotherapy.
Overall, the range of nanoparticle-based drug delivery Frontiers in Pharmacology, 2023. 14. systems for B.C. treatment is varied and encouraging. [6]Harbeck, N., et al., Breast cancer. Nature Reviews Disease
Several categories of nanoparticles, such as lipid-based Primers, 2019. 5(1): p. 66. nanoparticles (L.B.N.P.s), polymeric nanoparticles (PNPs), [7]Yang, F. et al., The potential role of nanomedicine in the and inorganic nanoparticles (I.N.P.s), are gaining recog- treatment of breast cancer to overcome the obstacles of current
nition for their substantial potential. L.B.N.P.s, including therapies. Frontiers in Pharmacology, 2023. 14. solid lipid nanoparticles (S.L.N.s), demonstrate exception- [8]Gao, Y., et al., Nanotechnology-based intelligent drug design al biocompatibility and adaptability, exhibiting potential for cancer metastasis treatment. Biotechnology Advances, 2014. for improving drug bioavailability and effectiveness. Poly- 32(4): p. 761-777. [9]Mundekkad, D. and W.C. Cho, Nanoparticles in Clinical Dean&Francis
Translation for Cancer Therapy. Int J Mol Sci, 2022. 23(3). Current Drug Development and Therapeutic Insight of Breast [10]Elumalai, K., S. Srinivasan, and A. Shanmugam, Review Cancer Treatment and Recommendations. Polymers (Basel),
of the efficacy of nanoparticle-based drug delivery systems for 2021. 13(24).
cancer treatment. Biomedical Technology, 2024. 5: p. 109-122. [19]Alshammari, B.H., et al., Organic and inorganic [11]Xu, L., et al., Lipid Nanoparticles for Drug Delivery. nanomaterials: fabrication, properties and applications. R.S.C.
Advanced NanoBiomed Research, 2022. 2(2): p. 2100109. Adv, 2023. 13(20): p. 13735-13785. [12]García-Pinel, B., et al., Lipid-Based Nanoparticles: [20]Bayda, S., et al., Inorganic Nanoparticles for Cancer Application and Recent Advances in Cancer Treatment. Therapy: A Transition from Lab to Clinic. Curr Med Chem,
Nanomaterials (Basel), 2019. 9(4). 2018. 25(34): p. 4269-4303. [13]Guney Eskiler, G. et al., Synthetically Lethal BMN 673 [21]Zhang, Y. et al., Targeting inorganic nanoparticles to tumors (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 using biological membrane-coated technology. MedComm,
Mutant Triple Negative Breast Cancer. Pharmaceutical Research, 2022. 3(4): p. e192. 2018. 35(11): p. 218. [22]Costas M. Pitsillides, E.K.J., Xunbin Wei, R. Rox Anderson, [14]Pindiprolu, S.K.S.S., et al., Formulation-optimization of and Charles P. Lin, Selective Cell Targeting with Lightsolid lipid nanocarrier system of STAT3 inhibitor to improve its Absorbing Microparticles and Nanoparticles. Biophysical 2003. activity in triple negative breast cancer cells. Drug Development 84: p. 4023-4032.
and Industrial Pharmacy, 2019. 45(2): p. 304-313. [23]Aghajanzadeh, M., et al., Synergic Antitumor Effect of [15]Afzal, M., et al., Nanomedicine in treatment of breast cancer Photodynamic Therapy and Chemotherapy Mediated by Nano – A challenge to conventional therapy. Seminars in Cancer Drug Delivery Systems. Pharmaceutics, 2022. 14(2): p. 322.
Biology, 2021. 69: p. 279-292. [24]Juarranz, Á., et al., Photodynamic therapy of cancer. Basic [16]Dristant, U., et al., An Overview of Polymeric principles and applications. Clinical and Translational Oncology,
Nanoparticles-Based Drug Delivery System in Cancer 2008. 10(3): p. 148-154.
Treatment. Technology in Cancer Research & Treatment, 2023. [25]Jadon, R.S. and M. Sharma, Docetaxel-loaded lipid-polymer 22: p. 15330338231152083. hybrid nanoparticles for breast cancer therapeutics. Journal of [17]Joshy, K.S., et al., An Overview of the Recent Developments Drug Delivery Science and Technology, 2019. 51: p. 475-484. in Hydrogels, in Nano Hydrogels: Physico-Chemical Properties [26]Wong, H.L., et al., A New Polymer–Lipid Hybrid and Recent Advances in Structural Designing, J. Jose, S. Nanoparticle System Increases Cytotoxicity of Doxorubicin
Thomas, and V.K. Thakur, Editors. 2021, Springer Singapore: Against Multidrug-Resistant Human Breast Cancer Cells.
Singapore. p. 231-246. Pharmaceutical Research, 2006. 23(7): p. 1574-1585. [18]Sartaj, A., et al., Polymeric Nanoparticles: Exploring the
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
